HLB Co Ltd 2023 SR
The report outlines HLB's transition into a global pharmaceutical leader, highlighting the progress of its anticancer drug Rivoceranib and its 2045 Net-Zero roadmap. Key achievements include receiving the 'Report of the Year' award at the 2023 Korea Management Awards and joining the UNGC 'Forward Faster' initiative. The company successfully installed a 100kW solar power facility, reducing GHG emissions by 21 tons, and achieved an 'A' rating from SUSTINVEST. HLB also conducted its first human rights impact assessment and established several new board committees to enhance governance transparency.
Company: HLB Co Ltd
Sector: Health Care
Country: South Korea
Year: 2023
Type: SR
Pages: 86
HLB Co Ltd
ESG Report
The report outlines HLB's transition into a global pharmaceutical leader, highlighting the progress of its anticancer drug Rivoceranib and its 2045 Net-Zero roadmap. Key achievements include receiving the 'Report of the Year' award at the 2023 Korea Management Awards and joining the UNGC 'Forward Faster' initiative. The company successfully installed a 100kW solar power facility, reducing GHG emissions by 21 tons, and achieved an 'A' rating from SUSTINVEST. HLB also conducted its first human rights impact assessment and established several new board committees to enhance governance transparency.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Jun 1, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees